Clinical Trial Update: Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating alternate dosing schedules of belantamab mafodotin for triple-class refractory multiple myeloma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING